1. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.
- Author
-
Moussa, Charbel, Hebron, Michaeline, Xu Huang, Ahn, Jaeil, Rissman, Robert A., Aisen, Paul S., Scott Turner, R., Huang, Xu, and Turner, R Scott
- Subjects
RESVERATROL ,ALZHEIMER'S disease ,ACTIVATORS (Chemistry) ,PLACEBOS ,NEURODEGENERATION ,METALLOPROTEINASES ,COGNITION disorders ,COMPARATIVE studies ,CYTOKINES ,ENCEPHALITIS ,GROWTH factors ,IMMUNITY ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,NERVE tissue proteins ,NONSTEROIDAL anti-inflammatory agents ,PEPTIDES ,PROTEOLYTIC enzymes ,PSYCHOLOGICAL tests ,RESEARCH ,ACTIVITIES of daily living ,STILBENE ,EVALUATION research ,BLIND experiment ,DISEASE complications ,PHARMACODYNAMICS ,THERAPEUTICS ,PSYCHOLOGY - Abstract
Background: Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores.Methods: For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF Aβ42 <600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated). We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases (MMPs) in parallel in CSF and plasma samples.Results: Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Aβ42 levels during the 52-week trial, but did not alter tau levels.Conclusions: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.Trial Registration: ClinicalTrials.gov NCT01504854. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF